Real-world SPECTRUM data shows strong fluid resolution and vision gains by week 12, with low adverse events and no retinal vasculitis. Welcome back to another Ophthalmology Times Europe Rapid Readout.
Real-world Spectrum data show aflibercept 8 mg boosts early vision and retinal anatomy in wet AMD, including switch patients. Welcome back to another Ophthalmology Times Europe Rapid Readout. In this ...
Not every patient with geographic atrophy (GA) fits neatly into the criteria used in the pivotal clinical trials that led to the FDA approval of pegcetacoplan and avacincaptad pegol. That gap shaped a ...
For Caroline R. Baumal, MD, a path from academic retina through industry leadership has brought her full circle—back to the ...
Three cases illustrate treatment switches and extension intervals across retinal vein occlusion, age-related macular degeneration, and diabetic retinopathy.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s ...
The phase 2 EVIAN study (Early Vitrectomy and Intravitreal Antibiotics for Post-Operative Exogenous Endophthalmitis) found ...
An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...
New real-world data from ASRS 2026 show nearly 40% of wet AMD patients go 180+ days without anti-VEGF treatment within a year ...
Geographic atrophy (GA), secondary to age-related macular degeneration (AMD), remains one of the most challenging conditions ...
A real-world Vestrum database analysis found pegcetacoplan was linked to better visual acuity outcomes in geographic atrophy, ...
Louie Cai, MD: Manual prescreening for clinical trials is very labor intensive, taking as long as 30 minutes to an hour per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results